Becton Dickinson and Co
NYSE:BDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
CN |
Becton Dickinson and Co
Total Liabilities
Becton Dickinson and Co
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Becton Dickinson and Co
NYSE:BDX
|
Total Liabilities
$29.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Liabilities
$19.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Liabilities
$25.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
13%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Liabilities
$34.6B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
6%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Total Liabilities
$1.7B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Liabilities
$2.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
|
Becton Dickinson and Co
Glance View
Founded in 1897, Becton Dickinson and Co., commonly known as BD, embarked on its journey with the vision to improve medical discovery and diagnostics. Over the decades, BD has transformed from a small syringe and needle manufacturer to a global leader in the medical technology industry. Situated in Franklin Lakes, New Jersey, BD has carved out a prominent place through its steadfast commitment to addressing health care workers' requirements and enhancing patient outcomes. The company's diversified portfolio spans across three major segments: BD Medical, BD Life Sciences, and BD Interventional. This trinity of divisions underscores BD's prowess in producing a broad range of medical supplies, laboratory equipment, and diagnostic products that find their way into hospitals, research facilities, and clinics worldwide. The company operates primarily by innovating and supplying products that are indispensable to everyday medical care and scientific research. BD’s robust revenue stream is bolstered by its strategic approach to integrating new technologies and acquiring innovative smaller companies that complement its core offerings. Through strategies like these, BD continuously adapts to the evolving healthcare landscape. Its products, such as advanced syringes, safety-engineered devices, and sophisticated laboratory equipment, are deeply embedded in the healthcare system, making BD a critical part of the global push for improved health outcomes. The company’s blend of consistent product demand and strategic innovations secures a stable financial footing, allowing it to invest further in research and development while extending its market reach across the globe.
See Also
What is Becton Dickinson and Co's Total Liabilities?
Total Liabilities
29.6B
USD
Based on the financial report for Dec 31, 2025, Becton Dickinson and Co's Total Liabilities amounts to 29.6B USD.
What is Becton Dickinson and Co's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
5%
Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Becton Dickinson and Co have been 2% over the past three years , and 5% over the past ten years .